文献速递乳腺MR

HER2(2+)/SISH阳性与HER2(3+)乳腺癌:治疗前MRI差异及治疗后MRI预测pCR的准确性

HER2 (2+)/SISH-positive vs. HER2 (3+) Breast Cancer: Pre-treatment MRI Differences and Accuracy of pCR Prediction on Post-treatment MRI.
PubMed 文献 · Acad Radiol · 2025-04-18

这项回顾性研究纳入301例接受新辅助化疗及手术的HER2阳性乳腺癌患者,比较HER2(2+)/SISH阳性与HER2(3+)亚型在治疗前MRI上的影像特征差异,并评估治疗后MRI预测病理完全缓解(pCR)的准确性及观察者间变异。HER2(3+)组pCR率显著更高(58.7% vs. 18.5%,p<0.001),治疗前MRI两组影像特征不同,但基于MRI的pCR预测效能相近,将近完全缓解(near-rCR)纳入标准可提高特异度但降低敏感度。

要点

  • HER2(3+)组pCR率58.7%,显著高于HER2(2+)/SISH+组的18.5%(p<0.001)。
  • 治疗前MRI上HER2(3+)组更常见非肿块强化(NME)(44.5% vs. 16.7%,p<0.001)及肿块伴NME(33.6% vs. 9.3%,p=0.005)。
  • 治疗后MRI评估的观察者间一致性为中等(κ=0.541-0.588)。

核心结论

  • 治疗前MRI显示HER2(2+)/SISH+与HER2(3+)乳腺癌具有不同的影像特征;尽管HER2(3+)组pCR率更高,但基于MRI的pCR预测在两个亚组间表现相似,将near-rCR纳入标准可提高特异度但降低敏感度。

研究设计与样本

  • 回顾性研究,纳入301例接受新辅助化疗及手术的HER2阳性乳腺癌患者(平均年龄54±10岁),治疗前MRI特征由共识判读分析,两名放射科医师独立评估治疗后MRI的退缩模式及按RECIST v1.1的缓解情况,并将完全缓解进一步分为rCR和near-rCR。

关键影像表现/征象

  • 治疗前MRI上HER2(2+)/SISH+肿瘤更多表现为单发肿块,而HER2(3+)肿瘤更多表现为非肿块强化(NME)(44.5% vs. 16.7%,p<0.001)及肿块伴NME(33.6% vs. 9.3%,p=0.005);治疗后MRI上HER2(2+)/SISH+肿瘤多呈简单向心性退缩,HER2(3+)肿瘤多表现为无强化。

诊断标准与关键数值

  • pCR定义为最终病理报告乳腺内无残留浸润性或原位肿瘤(ypT0);仅用rCR预测pCR的AUC范围为0.659至0.756;加入near-rCR后特异度提高但敏感度降低,其中一名阅片者AUC显著增加(p=0.011)。

临床应用与阅片要点

  • 阅片时应注意HER2(2+)/SISH+与HER2(3+)乳腺癌在治疗前MRI上的形态学差异,治疗后评估需关注退缩模式;采用rCR联合near-rCR标准判读pCR时,需权衡特异度提高与敏感度降低,并注意观察者间一致性仅为中等(κ=0.541-0.588)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To evaluate whether HER2 (human epidermal growth factor receptor 2) (2+)/SISH (silver-enhanced in situ hybridization)+ and HER2 (3+) breast cancers exhibit distinct imaging characteristics on pre-treatment MRI and assess differences in pCR (pathologic complete response) prediction accuracy on post-treatment MRI, considering interobserver variability.

METHODS: This retrospective study included 301 HER2-positive breast cancer patients (mean age, 54 ± 10 years) who underwent NAC and surgery. Pre-treatment MRI features were analyzed in consensus. Two radiologists independently assessed post-treatment MRI for shrinkage patterns and response according to RECIST v1.1, further categorizing complete responses into rCR (radiologic complete response) and near-rCR. Interobserver agreement was measured (Cohen's kappa), and pCR was defined as no residual invasive or in situ tumor in the breast (ypT0) on the final pathology report. Sensitivity, specificity, and AUC were used to evaluate pCR prediction.

RESULTS: Fifty-four patients had HER2 (2+)/SISH+ and 247 had HER2 (3+) tumors. pCR rates were significantly higher in HER2 (3+) (58.7% vs. 18.5%, p < 0.001). On pre-treatment MRI, HER2 (2+)/SISH+ tumors more often appeared as single masses, while HER2 (3+) tumors showed more NME (non-mass enhancement) (44.5% vs. 16.7%, p < 0.001) and mass with NME (33.6% vs. 9.3%, p = 0.005). Post-treatment MRI showed simple concentric shrinkage in HER2 (2+)/SISH+ and no enhancement in HER2 (3+). Agreement was moderate (κ = 0.541-0.588). For pCR prediction, rCR alone yielded AUCs ranging from 0.659 to 0.756. Adding near-rCR improved specificity but reduced sensitivity, with a significant AUC increase for one reader (p = 0.011).

CONCLUSION: Pre-treatment MRI revealed distinct imaging characteristics between subgroups. While pCR rates were higher in HER2 (3+), MRI-based pCR prediction showed similar performance, though near-rCR reduced sensitivity.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Park GE, Mun HS, Kim SH, et al. HER2 (2+)/SISH-positive vs. HER2 (3+) Breast Cancer: Pre-treatment MRI Differences and Accuracy of pCR Prediction on Post-treatment MRI. Acad Radiol. 2025. PMID: 40253219. doi:10.1016/j.acra.2025.04.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。